Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. - Wikidata - wikimedia - TriplyDB

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

http://www.wikidata.org/entity/Q37958036

about

Thalidomide-a notorious sedative to a wonder anticancer drug.The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells Emerging biological insights and novel treatment strategies in multiple myeloma.Cereblon in health and disease.Lenalidomide, an antiproliferative CLL drug.Chronic lymphocytic leukaemia

P2860

Q33956871-1346BDA8-D703-41B2-9306-A52245071F8D Q36165173-0D0511EA-5E95-41EE-9885-C69CE340CB28 Q38037600-CBC28D10-18AC-4C17-AAD3-723CDA41B56C Q38876495-477CCDEC-F1F3-4DCC-A166-A11101D78D71 Q42862574-41C9F82A-4F06-47B0-AFB5-62630ACBC4DF Q56270980-932B423A-A1B9-4023-93A1-447E17AFAE0E

P2860

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

http://www.wikidata.org/entity/Q37958036

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@en

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@nl

type

label

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@en

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@nl

prefLabel

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@en

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@nl

P1433

Q37958036-8CC2650F-F174-46D4-863C-B6329061BFA4

P1476

Q37958036-3D6270D4-C4A3-429F-B850-F7A569EA2684

P2093

Q37958036-7040358E-5449-4546-89EB-48D0166D9A24

Q37958036-861BDE7A-1C92-479F-8889-9CB8B7034009

P2860

Q37958036-0C48E612-6D02-444C-9275-F70D7AD2418F

Q37958036-0EE1E700-1FD2-4979-8C67-83F45590B7B9

Q37958036-15187E6B-7191-40F7-BA7D-AEF0454A8FA4

Q37958036-17C92812-3757-4040-8BE6-885B0D58085B

Q37958036-1EB5E713-89FC-4F88-8A2A-3F60C97197A8

Q37958036-27BBE867-0289-4562-B547-077AA7BC57C4

Q37958036-2846BE09-67DC-44DB-80DA-FB781E8226D4

Q37958036-3177A57B-9F84-4D12-BF3D-33B501D924EC

Q37958036-41CB7C59-971D-4D1F-B349-3B91B5BD8856

Q37958036-4678A0D2-BEA5-4CFC-BC22-7D5F6CB80AD3

P304

Q37958036-8D97B9A2-4D65-4715-99ED-177160E123C9

P31

Q37958036-13C9FEBA-4FD7-45EA-A5B8-0C351F979E98

P356

Q37958036-A87B70E9-D288-49E2-9D0F-71D024A84CA9

P407

Q37958036-8ED67F2A-915C-4E05-A31F-DD07B1C0B917

P433

Q37958036-B4E8A0F2-C6FF-41BC-A6BF-0B54ABAD33CC

P478

Q37958036-4F27137E-1796-4197-BCEA-219D5BAF006D

P50

Q37958036-78B42661-1BFB-42B7-AEBF-22E377CAC0CB

P577

Q37958036-E7480DE0-712F-4AB6-A255-BFA719B83D17

P698

Q37958036-5462B620-FB99-4FBD-AB42-DA7C0C23D99F

P921

Q37958036-34CD25D6-E7DD-438D-82A3-2AEE40FBC6E7

Q37958036-4A8B280A-3C6A-4076-AEF6-49864873C144

Q37958036-9405F685-9333-4650-91F1-5D0B2AE0C01B

P356

14656566.2011.635644

P1433

Expert Opinion on Pharmacotherapy

P1476

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

@en

P2093

Daniel Mertens

http://www.w3.org/2001/XMLSchema#string

Krzysztof Giannopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

P304

2857-2864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.635644

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Stephan Stilgenbauer

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22098228

http://www.w3.org/2001/XMLSchema#string

P921